ER
HZNP

Enlightenment Research’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Enlightenment Research’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,000
Closed -$20K – 803
2018
Q4 		$20K Buy
+1,000
New +$19.6K 0.02% 466

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Enlightenment Research's HZNP Position: Q1 2019 in Review

Enlightenment Research sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2019, closing a stake of 1,000 shares — an estimated $20K sold.

Enlightenment Research first reported a position in HZNP in Q4 2018 and held it in 1 quarter. The position peaked at $20K in Q4 2018. 297 funds tracked by Wall St. Rank hold HZNP as of Q1 2019.

  • Enlightenment Research reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2019 after selling out during the quarter.
  • Enlightenment Research sold 1,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2019, an estimated $20K.
  • Enlightenment Research first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2018 and held it in 1 quarter.
  • Enlightenment Research's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $20K in Q4 2018.
  • 297 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2019.

Based on Enlightenment Research's 13F filing for Q1 2019, filed 3 May 2019.